5 Best Stocks To Buy According To 4 Billionaire Quants
What are the best stocks to buy? The Wisdom of Crowds: Why the Many Are Smarter Than The Few and How Collective Wisdom Shapes Business, Economies, Societies and Nations is James...
Posts Tagged ‘NASDAQ:AMGN’
Five Best Stocks to Buy According To Quant Billionaires
One of the best ways to pick high-performing stocks is to follow the industry leaders and find out their stock investments.
Billionaire Dan Loeb Slightly Shuffles Third Point’s Top Picks, Selling Off Large Alibaba Group Holding Ltd (BABA) Stake
Famous billionaire activist hedge-fund manager Dan Loeb of Third Point is renowned for the bombshells that he drops on the management of his target companies in the form of letters...
United Therapeutics Corporation (UTHR), Amgen, Inc. (AMGN): Neil Shah’s Top Healthcare Picks Dominated S&P 500 Index in January-March
March Altus Capital Management, headquartered in Greenwich, Connecticut, was founded by Neil Shah in December 2011.This healthcare focused fund follows bottom-up fundamental analysis...
Ariad Pharmaceuticals, Inc. (ARIA), Amgen, Inc. (AMGN): How Sarissa Capital’s Top Picks Beat the Market
Headquartered in Connecticut, Sarissa Capital Management was founded by Alexander J. Denner in 2012. Prior to this, Mr.
Huge Losses in Alibaba Group Holding Ltd (BABA) Not Enough to Stop Billionaire Dan Loeb from Beating the Market
Considering that the second-largest holding of Dan Loeb's Third Point, Alibaba Group Holding Ltd (NYSE:BABA), lost 19.92% of its stock value during the first quarter, the fund...
Healthcare Hedge Fund Orbimed’s Top Picks and New Move
According to a Schedule 13D form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals...
Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires’ 5 Hottest Biotech Picks
With the high volatility prevalent in the biotechnology sector, investors have a hard time picking the right stocks to invest in.
Ariad Pharmaceuticals, Inc., Quest Diagnostics Inc, Amgen, Inc.: Sarissa Capital’s Top Stock Picks and New Moves
Alex Denner’s Sarissa Capital Management recently disclosed its stock picks for the fourth quarter of 2014 in a 13F Form filed with the U.S.
Billionaire Dan Loeb`s Third Point Looks to Rebound From Poor Year With Top Picks: Alibaba Group Holding Ltd (BABA), Amgen, Inc. (AMGN), Dow Chemical Co (DOW)
Dan Loeb`s Third Point filed its latest 13F with the SEC last week, detailing its long positions at the end of a self-admittedly poor year for the fund.
Amgen, Inc. (AMGN)’s Drug Trial Fails To Live Up To Expectation
Shares of Amgen, Inc.
Amgen, Inc. (AMGN) Announces Revenue Growth And Profitability In The Second Quarter
Amgen, Inc. (NASDAQ:AMGN) announced its second quarter financial results on July 29, 2014. Amgen's total revenues increased by 11% on the year to $5.18 billion.
Stuart Weisbrod’s Iguana Healthcare Management Is Fond of These Stocks
New York City-based Iguana Healthcare Management was founded by Stuart Weisbrod in 2010.
Is PowerShare Buyback Achievers Fund a Buy? The Safest Way To Profit From $455 Billion In Stock Buybacks
Over the past few years at StreetAuthority, we've been chronicling the remarkable pace of share buybacks.
Amgen, Inc. (AMGN)’s Potential Promise
Last Friday, Zacks released a new report were it reconfirmed its neutral rating for Amgen, Inc. (NASDAQ:AMGN).
Omthera Pharmaceuticals Inc (OMTH), Elan Corporation, plc (ADR) (ELN), Onyx Pharmaceuticals, Inc. (ONXX): 3 Big Biotech Buyouts of 2013
The Chinese calendar says 2013 is the year of the snake, but the market says it's the year of biotech.
Amgen, Inc. (AMGN), Impax Laboratories Inc (IPXL): Keryx Biopharmaceuticals (KERX)’s Stifel Conference Presentation
There were definitely some good parts in what Keryx Biopharmaceuticals (NASDAQ:KERX) had to say at this week's Stifel Nicolaus Weisel Healthcare Conference in Boston.
Bristol Myers Squibb Co. (BMY), Merck & Co., Inc. (MRK): Is AstraZeneca plc (ADR) (AZN)’s Recent Acquisition Bigger Than Onyx?
AstraZeneca plc (ADR) (NYSE:AZN) may have missed out on acquiring the oncology platform of Onyx Pharmaceuticals, but it responded by pulling the trigger on a $500 million deal...
Amgen, Inc. (AMGN), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): The Neulasta Question
In a couple of years, Amgen, Inc. (NASDAQ:AMGN) will have to face the music when the patent for its $4 billion a year drug, Neulasta, expires in the U.S. and Europe.
Aegerion Pharmaceuticals, Inc. (AEGR): Cheers and Jeers for Amgen, Inc. (AMGN)’s Pipeline
Just after the successful acquisition of Onyx Pharmaceuticals and positive results on AMG-145, a cholesterol-lowering experimental drug, Amgen, Inc.
Pfizer Inc. (PFE), Regeneron Pharmaceuticals Inc (REGN), Amgen, Inc. (AMGN): Invest in the Next Biotech Frontier
The last several months have been remarkably exciting in the biotech space.
Cytokinetics, Inc. (CYTK), Amgen, Inc. (AMGN): Digging Deeper Into This Heart Failure Drug’s Miss
Before the market opened last Tuesday, Cytokinetics, Inc. (NASDAQ:CYTK) and Amgen, Inc.
Alexion Pharmaceuticals, Inc. (ALXN), Amgen, Inc. (AMGN), Baxter International Inc. (BAX): The Treatment of Rare Diseases Offers Unique Opportunities
A company with a modus operandi of tackling rare and very rare diseases might not necessarily jump out as a great investment, but this company has banked more than a billion...
MiMedx Group Inc (MDXG), Cytokinetics, Inc. (CYTK), Amgen, Inc. (AMGN): A Trio of Horrendous Health-Care Stocks This Week
College football arrived in a big way over the past week or so, with plenty of big plays already.
Astex Pharmaceuticals, Inc. (ASTX) Becomes the Latest Biotech Domino to Fall
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Two Reasons This Biotech Hardly Moved After a Successful Trial
Adding Esperion Therapeutics' ECT-1002 to Pfizer Inc. (NYSE:PFE)'s Lipitor lowered bad LDL cholesterol levels by 22%.
Eli Lilly & Co. (LLY), Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Where We’re Headed
Over the past couple of months we've discussed many of the biggest risk factors associated with some of the leading causes of death in the United States -- heart disease, cancer...
Amgen, Inc. (AMGN), Astex Pharmaceuticals, Inc. (ASTX), Pharmacyclics, Inc. (PCYC): This Week in Biotech
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Celgene Corporation (CELG), Cytokinetics, Inc. (CYTK), Astex Pharmaceuticals, Inc. (ASTX): Is the Biotech Bubble About to Burst?
"Bubble" can be a provocative word in investing circles. Think of all that comes to mind when you hear it -- perhaps other words like over-hyped, overvalued, risky, etc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Monday’s Best Stocks
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Amgen, Inc. (AMGN), Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Onyx Pharmaceuticals, Inc. (ONXX): This Biotech Envisions Green
After a second offer, Amgen, Inc. (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc.
The Amgen, Inc. (AMGN)-Onyx Pharmaceuticals, Inc. (ONXX) Deal Should Make All Biotech Investors Happy
While that's certainly not what Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors were hoping for -- at one point, after Amgen, Inc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX), NASDAQ OMX Group, Inc. (NDAQ): Deals, Not Data, Drive Dow Today
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Amgen, Inc. (AMGN): Is Galena Biopharma Inc (GALE)’s Big Break Just Around the Corner?
Judging by the numbers, Galena Biopharma Inc (NASDAQ:GALE) isn't exactly a stock many would call great.
Amgen, Inc. (AMGN) and Onyx Pharmaceuticals, Inc. (ONXX): Half a Billion Dollars’ Worth of Drama
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals, Inc.
What Is Amgen, Inc. (AMGN) Getting For Its Money?
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN), Microsoft Corporation (MSFT): Stocks to Watch Closely Today
Since the first day of the week can predict the flow of the whole week, it is particularly crucial to focus on Monday news and events.
Pfizer Inc. (PFE), Amgen, Inc. (AMGN), UnitedHealth Group Inc. (UNH): Do Health Care Stocks Fall in the Fall?
Every investor has heard the old line "sell in May and go away." That wasn't such great advice this year with the S&P 500 index up nearly 5% since the beginning of May.
Hedge Funds Are Buying Amgen, Inc. (AMGN)
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Amgen, Inc. (AMGN), AstraZeneca plc (ADR) (AZN): What’s the Big Deal About Onyx Pharmaceuticals, Inc. (ONXX) Anyway?
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc.
This Biogen Idec Inc. (BIIB) Data is Screaming ‘Buy, Buy, Buy’
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Medivation Inc (MDVN), Seattle Genetics, Inc. (SGEN) – Biotech Buyouts: Who’s Next?
There's been plenty of buzz lately about the continuing saga of the possible buyout of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (NASDAQ:AMGN).
Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Settled Stock & Amgen, Inc. (AMGN)’s Clinical Trial
Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw new options become available this week, for the April 2014 expiration. ...VIVUS, Inc.
Is Celgene Corporation (CELG) Going to Burn You?
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Green Mountain Coffee Roasters Inc. (GMCR), Gilead Sciences, Inc. (GILD): Investing in Quality Stocks — Made Easy
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Novartis AG (ADR) (NVS), Amgen, Inc. (AMGN): Incyte Corporation (INCY) Jumps on Jakafi Results
Incyte Corporation (NASDAQ:INCY) today announced positive results from a phase 2 study of its drug Jakafi in treating refractory metastatic pancreatic cancer.
Who’s Betting On Gilead Sciences, Inc. (GILD)?
If you were to ask many investors, hedge funds are seen as delayed, old financial vehicles of an era lost to time.
Pfizer Inc. (PFE), Regeneron Pharmaceuticals Inc (REGN): Are These Drugs the Future of High-Cholesterol Treatment?
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
